FilamenTech
FilamenTech is a biomedical software and research company that develops multiscale computational models and analysis tools for muscle structure and function. The organization provides simulation-driven workflows that translate molecular- and genetic-level changes into predictions of muscle and whole-organ behavior, supports in‑silico drug testing and personalized treatment strategy development, and couples simulation outputs with experimental data and finite-element models.
Industries
Nr. of Employees
small (1-50)
FilamenTech
140 Pearl St., Newton MA 02458, USA
Products
Multiscale muscle simulation platform
A modular simulation software suite for modeling muscle systems from molecular kinetics to whole-organ mechanics, including modules for solution-level assays, motility assays, 3D sarcomere/fiber modeling, X-ray diffraction prediction, and surrogate/FE coupling.
Multiscale muscle simulation platform
A modular simulation software suite for modeling muscle systems from molecular kinetics to whole-organ mechanics, including modules for solution-level assays, motility assays, 3D sarcomere/fiber modeling, X-ray diffraction prediction, and surrogate/FE coupling.
Services
Custom simulations and analyses that translate molecular or genetic changes into predictions of muscle and organ function.
Simulation-based assessment of small-molecule effects on muscle function across scales to prioritize compounds and evaluate dose effects.
Prediction and interpretation of small-angle X-ray fiber diffraction patterns from muscle to extract structural and force-related information.
Integration of patient genomic data with multiscale models to evaluate mutation impact and support personalized therapeutic strategies.
Generation of surrogate models and coupling interfaces to embed multiscale muscle model outputs into finite-element simulations for tissue or organ analysis.
Design of experiments (motility assays, stopped-flow, ATPase, fiber mechanics, X-ray diffraction) and multiscale data analysis to provide inputs and validation for models.
Custom simulations and analyses that translate molecular or genetic changes into predictions of muscle and organ function.
Simulation-based assessment of small-molecule effects on muscle function across scales to prioritize compounds and evaluate dose effects.
Prediction and interpretation of small-angle X-ray fiber diffraction patterns from muscle to extract structural and force-related information.
Integration of patient genomic data with multiscale models to evaluate mutation impact and support personalized therapeutic strategies.
Generation of surrogate models and coupling interfaces to embed multiscale muscle model outputs into finite-element simulations for tissue or organ analysis.
Design of experiments (motility assays, stopped-flow, ATPase, fiber mechanics, X-ray diffraction) and multiscale data analysis to provide inputs and validation for models.
Expertise Areas
- Multiscale computational modeling
- In-silico drug testing and virtual trials
- Muscle biomechanics and physiology
- X-ray fiber diffraction modeling and analysis
Key Technologies
- Multiscale simulation frameworks
- Surrogate modeling
- Finite element coupling
- High-performance C++ implementations
News & Updates
Participation in the project “Analysis Tools for Fiber Diffraction of Muscle” (R01GM144555) supported by NIGMS/NIH.
Collaboration to perform simulations and data analysis for optimization of DiGS experiments conducted on Earth and at the ISS.
Completion of the SilicoFCM project on in-silico trials for tracing effects of sarcomeric protein mutations leading to familial cardiomyopathy (Horizon 2020, No 777204).
Contributed to multiple funded projects (e.g., NIH R01GM144555, AHA project, Horizon 2020 SilicoFCM) to develop analysis tools for muscle diffraction and in-silico trials.
Participation in the project “Analysis Tools for Fiber Diffraction of Muscle” (R01GM144555) supported by NIGMS/NIH.
Collaboration to perform simulations and data analysis for optimization of DiGS experiments conducted on Earth and at the ISS.
Completion of the SilicoFCM project on in-silico trials for tracing effects of sarcomeric protein mutations leading to familial cardiomyopathy (Horizon 2020, No 777204).
Contributed to multiple funded projects (e.g., NIH R01GM144555, AHA project, Horizon 2020 SilicoFCM) to develop analysis tools for muscle diffraction and in-silico trials.